About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Drug Everolimus Does Not Improve Overall Survival in Advanced Liver Cancer Patients

by Bidita Debnath on July 2, 2014 at 8:59 PM
Font : A-A+

 Drug Everolimus Does Not Improve Overall Survival in Advanced Liver Cancer Patients

A study in the July 2 issue of JAMA reveals that despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo.

Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve overall survival in advanced HCC; however its benefits are mostly transient and modest, and disease eventually progresses. In preclinical models, everolimus prevented tumor progression and improved survival, according to background information in the article.

Advertisement

Andrew X. Zhu, M.D., Ph.D., of the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, and colleagues randomly assigned 546 adults with advanced HCC whose disease progressed during or after sorafenib or who were intolerant of sorafenib to receive everolimus (n = 362) or placebo (n = 184), both given in combination with best supportive care and continued until disease progression or intolerable toxicity. In this phase 3 study, patients were enrolled from 17 countries between May 2010 and March 2012.

The researchers found no significant difference in overall survival between the two groups: there were 303 deaths (83.7 percent) in the everolimus group and 151 deaths (82.1 percent) in the placebo group. Median overall survival was 7.6 months with everolimus, 7.3 months with placebo. The disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease) was 56.1 percent (everolimus) and 45.1 percent (placebo).
Advertisement

"The results from [this study, EVOLVE-1] extend the list of failed phase 3 studies in advanced HCC, highlighting the challenge of developing effective therapies for this cancer," the authors write.

The researchers note that EVOLVE-l and the other failed phase 3 studies have provided several important lessons, including that it is difficult to assess efficacy signals from phase 2 trials; surrogate end points such as time to progression, progression-free survival, and response rate inconsistently predict overall survival in phase 3 trials; and clinical and biologic heterogeneity likely affects the performance of targeted therapies in HCC. "In the absence of well-characterized and validated predictive bio-markers, targeted agents will likely continue to have a high risk of failure if phase 3 trials are conducted in unselected populations."

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alcoholic Liver Disease Drug Toxicity Hepatitis A Hepatitis B Liver Cancer Cancer and Homeopathy Neonatal Jaundice Bubbles and Brews - Alcohol Facts Signature Drug Toxicity Cancer Facts 

Recommended Reading
Risk of Liver Cancer Lower Among Chronic Hepatitis B Patients Who Undergo Antiviral Therapy
Undergoing antiviral therapy can reduce the risk of liver cancer among patients who have chronic ......
Antiviral Therapy may Prevent Liver Cancer in Patients Suffering from Hepatitis B
Scientists have found that antiviral therapy may be successful to prevent hepatitis B virus from ......
Liver Cancer Vaccine Effective at Preventing the Disease in Mice
Tweaking a protein expressed by most liver cancer cells has helped researchers to make a vaccine ......
Tough Liver Cancer to Now be Tackled by Immunotherapy
A new study has revealed that tough liver cancer (Hepatocellular Carcinoma) can now be tackled by .....
Alcoholic Liver Disease
Encyclopedia section of medindia gives general information about Alcoholic Liver Disease....
Bubbles and Brews - Alcohol Facts
There is more to alcohol than mere intoxication. Infamous because of its social abuse but indispensa...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. H...
Hepatitis B
Hepatitis B is inflammation of the liver due to infection with the hepatitis B virus....
Liver Cancer
Liver or hepatic cancer is an abnormal growth of cells in the liver. The leading cause of the diseas...
Neonatal Jaundice
Yellow colouring of skin in newborns, a condition called Neonatal jaundice. , Neonatal jaundice is c...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use